Immune Response News and Research

RSS

Two anti-inflammatory drugs reduce deaths in severe COVID-19 patients

Two anti-inflammatory drugs, abatacept and infliximab, reduced deaths among patients hospitalized with severe COVID-19, according to a national study led by Washington University School of Medicine in St. Louis. William G. Powderly, MD, (right) who led the large clinical trial, discusses patient conditions with Maanasi Samant, MD, in the intensive care unit at Barnes-Jewish Hospital, one of the major trial sites, during the COVID-19 pandemic.

10 Jul 2023

Prolonged T-cell response during severe COVID-19 does not contribute to long COVID

Persistent immune activation and elevated cytokine levels were observed in patients with severe COVID-19, even months after recovery. However, the correlation between immune activation and long COVID symptoms appeared to be independent, suggesting other factors influencing disease severity.

9 Jul 2023

Novel approach sheds light on the interactions between SARS-CoV-2 viruses and human placenta

Until now, scientific evidence has been inconclusive regarding the ability of SARS-CoV-2, the virus that causes COVID, to replicate in the human placenta.

7 Jul 2023

Unique blood protein patterns in long COVID patients could reveal potential drug targets

Recently published in The Journal of Translational Medicine, a team at Lawson Health Research Institute has discovered unique patterns of blood plasma proteins in patients with long COVID that could reveal potential drug targets to improve patient outcomes.

7 Jul 2023

Unlocking the immune puzzle: study evaluates the immune impact of second booster COVID-19 vaccine

Researchers assessed acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant of concern (VOC).

6 Jul 2023

Using a vaccine to boost the response of engineered T cells

Engineering T cells to destroy cancer cells has shown success in treating some types of cancer, such as leukemia and lymphoma. However, it hasn't worked as well for solid tumors.

5 Jul 2023

Candidate genes for inflammatory bowel disease identified

A study of the genetic variation that makes mice more susceptible to bowel inflammation after a high-fat diet has identified candidate genes which may drive inflammatory bowel disease (IBD) in humans. The findings are published as a Reviewed Preprint in eLife.

5 Jul 2023

Study shows how glutamine can help or hinder cancer-killing activity

Scientists at St. Jude Children's Research Hospital found immune and tumor cells compete over glutamine, a major nutrient in their local environment, with significant implications for anti-cancer activity.

5 Jul 2023

Purecap method offers hope for purer and safer mRNA vaccines

A research group from Japan has developed a method to produce highly active mRNA vaccines at high purity using a unique cap to easily separate the desired capped mRNA.

5 Jul 2023

Reproductive impact of changes in the vaginal microbiome of obese women

Study explores the impact of obesity on vaginal microbiota and reproduction.

5 Jul 2023

Immune inflammatory reaction to COVID-19 may not be the underlying cause of long Covid

Long Covid, which affects nearly two-million people in the UK, is not caused by an immune inflammatory reaction to COVID-19, University of Bristol-led research finds.

4 Jul 2023

Spanish researchers develop new immunotherapy combination for liver cancer

Spanish researchers at Cima University of Navarra have developed a new immunotherapy combination that improves efficacy in animal models of hepatocellular carcinoma. This is a proof of concept that lays the foundations for the application of this treatment in patients with the most common liver cancer.

1 Jul 2023

Towards Zika preparedness: immunogenicity insights from vaccine research

Study assesses the safety and immunogenicity of an inactivated Zika virus vaccine candidate.

30 Jun 2023

Advances in influenza research

This interview with Dr. Mohammad S Safiarian, Associate Product Manager at Sino Biological, discusses the advances in influenza research and how effective vaccines are developed.

From Sino Biological Inc. 30 Jun 2023

Albumedix and Valneva expand collaboration to include newly approved inactivated COVID-19 vaccine

Albumedix Ltd., a recognized global leader in Recombinant Human Albumin (rHA), specializing in the enablement of advanced therapies and biopharmaceuticals, today announces the expansion of its existing collaboration with Valneva SE, a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need.

From Albumedix Ltd. 29 Jun 2023